JanetChandlerDuboisMD

Dermatology • Austin, TX

Physician

Join to view full profile

Dr. Dubois is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dubois' full profile

Already have an account?

Office
8140 North Mopac
Building 3, Suite 120
Austin, TX 78759
Phone+1 512-349-9889

Fax+1 512-349-9559

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 1988 - 1991
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1987 - 1988
The University of Texas Health Science Center at San AntonioClass of 1987

Certifications & Licensure

TX State Medical License 1995 - 2025
WA State Medical License 1991 - 1994
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Start of enrollment: 2014 Jan 01
Completed
Phase 2
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
Completed
Phase 2
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
Study of Glycopyrronium in Axillary Hyperhydrosis Start of enrollment: 2015 Jul 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2) Start of enrollment: 2016 Feb 01
Completed
Phase 2
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp Start of enrollment: 2017 Mar 01
Withdrawn
Phase 3
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Start of enrollment: 2019 Jun 27
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Michael Gold, Joel Schlessinger, Greg J Goodman, Steven Dayan, Janet DuBois
Aesthetic Surgery Journal. 2025-03-04
1 citations
Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cmof the face or scalp in patients with actinic keratosis: A phase 3 study.
Neal Bhatia, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit
JAAD International. 2024-12-01
Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomyc...
Amir Tavakkol, Janet C DuBois, Aditya K Gupta
Antimicrobial Agents and Chemotherapy. 2024-10-08

Press Mentions

Promising SK Drug’s Trials Enter Final PhasesMarch 3rd, 2015
Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group StudyAugust 21st, 2019
Vial Launches Innovative Dermatology CRO January 27th, 2022

Professional Memberships

American Academy of Dermatology - AAD
Fellow